Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here is one stock under $50 that could 10x and two that could be down big.
Two Stocks Under $50 to Sell:
Kemper (KMPR)
Share Price: $28.43
Originally known as Unitrin until rebranding in 2011, Kemper (NYSE:KMPR) is an insurance holding company that provides automobile, homeowners, life, and other insurance products to individuals and businesses across the United States.
Why Is KMPR Risky?
- 3.3% annual declines in net premiums earned for the past five years indicates policy sales struggled this cycle
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 14.5% annually, worse than its revenue
- Annual book value per share declines of 11.3% for the past five years show its capital management struggled during this cycle
Kemper is trading at $28.43 per share, or 0.7x forward P/B. To fully understand why you should be careful with KMPR, check out our full research report (it’s free).
Murphy Oil (MUR)
Share Price: $39.57
Operating in waters over a mile deep in the Gulf of Mexico and extracting hydrocarbons from tight shale rock formations in Texas, Murphy Oil (NYSE:MUR) explores for and produces crude oil, natural gas, and natural gas liquids from fields in North America and Asia.
Why Is MUR Not Exciting?
- Costs have risen faster than its revenue over the last five years, causing its EBITDA margin to decline by 5.1 percentage points
At $39.57 per share, Murphy Oil trades at 9.3x forward P/E. Dive into our free research report to see why there are better opportunities than MUR.
One Stock Under $50 to Watch:
Hims & Hers Health (HIMS)
Share Price: $29.13
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Could HIMS Be a Winner?
- Customer trends over the past two years show it’s maintaining a steady flow of new contracts that can potentially increase in value over time
- Free cash flow margin increased by 15.9 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Historical investments are beginning to pay off as its returns on capital are growing
Hims & Hers Health’s stock price of $29.13 implies a valuation ratio of 21.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.